JUST RELEASED: Castle Biosciences announces financial results for the 3rd quarter and nine months ended 9/30/26
Q3 2026 Highlights: Revenue of $102.9 million; TissueCypher® test report volume increased 47% over Q3 2025; raising full-year 2026 revenue guidance to $385-395 million from $365-375 million, as of 9/30/26
View further results and access the webcast here: ir.castlebiosciences.com/news-events/pr…
Q3 2026 Highlights: Revenue of $102.9 million; TissueCypher® test report volume increased 47% over Q3 2025; raising full-year 2026 revenue guidance to $385-395 million from $365-375 million, as of 9/30/26
View further results and access the webcast here: ir.castlebiosciences.com/news-events/pr…